Home Cart 0 Sign in  
X

[ CAS No. 5157-08-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 5157-08-4
Chemical Structure| 5157-08-4
Chemical Structure| 5157-08-4
Structure of 5157-08-4 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 5157-08-4 ]

Related Doc. of [ 5157-08-4 ]

Alternatived Products of [ 5157-08-4 ]

Product Details of [ 5157-08-4 ]

CAS No. :5157-08-4 MDL No. :MFCD00006455
Formula : C5H8N2O Boiling Point : -
Linear Structure Formula :- InChI Key :VOTFXESXPPEARL-UHFFFAOYSA-N
M.W : 112.13 Pubchem ID :78834
Synonyms :

Calculated chemistry of [ 5157-08-4 ]

Physicochemical Properties

Num. heavy atoms : 8
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.6
Num. rotatable bonds : 0
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 37.96
TPSA : 41.46 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -7.5 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.16
Log Po/w (XLOGP3) : -0.73
Log Po/w (WLOGP) : -0.49
Log Po/w (MLOGP) : -0.08
Log Po/w (SILICOS-IT) : 1.48
Consensus Log Po/w : 0.27

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -0.08
Solubility : 94.3 mg/ml ; 0.841 mol/l
Class : Very soluble
Log S (Ali) : 0.34
Solubility : 243.0 mg/ml ; 2.17 mol/l
Class : Highly soluble
Log S (SILICOS-IT) : -1.29
Solubility : 5.75 mg/ml ; 0.0513 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 2.55

Safety of [ 5157-08-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 5157-08-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 5157-08-4 ]
  • Downstream synthetic route of [ 5157-08-4 ]

[ 5157-08-4 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 5157-08-4 ]
  • [ 65202-58-6 ]
Reference: [1] Patent: EP3333157, 2018, A1,
  • 2
  • [ 5157-08-4 ]
  • [ 13327-27-0 ]
YieldReaction ConditionsOperation in experiment
68% at 90℃; for 6 h; To a solution of 6-methyl-4,5-dihydropyridazin-3(2H)-one (9.0 g, 80.26 mmol) in acetic acid (90 mL) was dropwise added bromine (7.68 g, 48.05 mmol) at 90 °C and the reaction mixture was stirred at 90 °C for 5-6 h. The excess of acetic acid was removed and the resultant residue was treated with an aqueous solution of sodium bicarbonate, filtered and the filter cake was dried to afford the title product (6.0 g, 68percent). 1H NMR (300 MHz, DMSO-d6): δ 12.73 (s, 1H), 7.30 (d, J = 9.6 Hz, 1H), 6.80 (d, J = 9.9 Hz, 1H), 2.14 (s, 3H).
20 g at 80℃; for 0.5 h; Example 13A (23g, 205.4mmol) was dissolved in acetic acid (100mL) and liquid bromine (55.03g, 348.5mmol)was added dropwise to the above solution under vigorous stirring. The temperature during the dropwise addition did notexceed 40°C. After the addition, the mixture was reacted at 80°C for half an hour, cooled to room temperature, filteredand the filter cake was rinsed twice with methyl tert-butyl ether to give the title compound (20g, yield 87percent) which wasused directly in the next step without further purification. LCMS (ESI) m/z: 133[M+1]+. 1HNMR (CHLOROFORM-d, BrukerAvance 400MHz): ppm 7.36-7.39 (m, 1H), 6.69-6.89 (m, 1H), 2.22 (s, 3H).
Reference: [1] Bioorganic and Medicinal Chemistry Letters, 2012, vol. 22, # 19, p. 6286 - 6291
[2] Journal of Chemical Research, Miniprint, 1995, # 8, p. 1840 - 1852
[3] Journal of the Chemical Society, 1947, p. 239,242
[4] Journal of the Chemical Society, 1947, p. 239,242
[5] Patent: US4595521, 1986, A,
[6] Patent: US4255571, 1981, A,
[7] European Journal of Medicinal Chemistry, 2013, vol. 64, p. 512 - 528
[8] Patent: EP3333157, 2018, A1, . Location in patent: Paragraph 0134; 0135
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 5157-08-4 ]

Amides

Chemical Structure| 108-26-9

[ 108-26-9 ]

3-Methyl-1H-pyrazol-5(4H)-one

Similarity: 0.85

Chemical Structure| 137-44-0

[ 137-44-0 ]

1H-Pyrazol-5(4H)-one

Similarity: 0.73

Chemical Structure| 1071-93-8

[ 1071-93-8 ]

Adipohydrazide

Similarity: 0.65

Chemical Structure| 6304-39-8

[ 6304-39-8 ]

Octanehydrazide

Similarity: 0.65

Chemical Structure| 4146-43-4

[ 4146-43-4 ]

Succinic Dihydrazide

Similarity: 0.62

Related Parent Nucleus of
[ 5157-08-4 ]

Pyridazines

Chemical Structure| 1292369-21-1

[ 1292369-21-1 ]

4-Ethylpyridazin-3(2H)-one

Similarity: 0.62

Chemical Structure| 33471-40-8

[ 33471-40-8 ]

4-Methylpyridazin-3(2H)-one

Similarity: 0.61

Chemical Structure| 101328-85-2

[ 101328-85-2 ]

(R)-6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one

Similarity: 0.61

Chemical Structure| 36725-28-7

[ 36725-28-7 ]

6-(4-Aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one

Similarity: 0.61

Chemical Structure| 54709-94-3

[ 54709-94-3 ]

5-Methylpyridazin-3(2H)-one

Similarity: 0.60